Tesamorelin plus ipamorelin 1:1 blend (tesamorelin amount)
Timing: Ipamorelin rises with tesamorelin in a 1:1 blend, which is why blend doses run far below solo doses.
Also known as: Tesamorelin acetate · TH9507 · Tesa · Egrifta · Egrifta SV · Egrifta WR
Updated 29 sources
Every Tesamorelin protocol on file, 11 in all, labelled by where each number came from. 1 have titration steps, each step is worked out in U-100 units for a 2 mg vial + 0.5 mL water.
Timing: Ipamorelin rises with tesamorelin in a 1:1 blend, which is why blend doses run far below solo doses.
Who: Adults with HIV and excess abdominal fat (lipodystrophy)
Who: Adults with HIV and lipodystrophy
Timing: Into the abdomen, rotating sites. No time of day is specified. Same exposure as 2 mg of the original formulation.
Who: Adults with HIV and lipodystrophy
Timing: Same exposure as 2 mg of the original formulation. Not interchangeable with Egrifta SV.
Who: Forum protocols compiled in a 2026 peer-reviewed review
Who: 41 repeat reporters on a self-logging tracker; reports span 0 to over 5 mg
Timing: Before bed, fasted 2 or more hours after a meal. The 1 mg start is optional.
| When | Dose | U-100 units (2 mg vial + 0.5 mL water) |
|---|---|---|
| Weeks 1 to 2 | 1 mg | 25 units · 0.25 mL |
| Weeks 3 to 12 | 2 mg | 50 units · 0.5 mL |
Timing: Morning, fasted. Start at 1 mg, then move to 2 mg.
Timing: Fasted 2 or more hours. 2 mg is standard; drop to 1 mg if IGF-1 is above range. The guide sees no benefit above 2 mg.
Doses shown are what sources report, labelled by origin. Not medical advice.
| Goal | Most reported amounts (mentions) |
|---|---|
| Goal not stated | 2 mg (105), 1 mg (104), 0.5 mg (18), 1.5 mg (9) |
| Weight loss | 1 mg (37), 2 mg (34), 0.5 mg (7), 500 mcg (4) |
| Muscle growth | 1 mg (9), 2 mg (9), 500 mcg (2) |
| Water | Strength | 1 mgdose, units | 1.4 mgdose, units | 2 mgdose, units |
|---|---|---|---|---|
| 2 mg vial | ||||
| 0.5 mLRegulatory | 4 mg/mL | 250.25 mL | 350.35 mL | 500.5 mL |
| 1 mLCompetitor guide | 2 mg/mL | 500.5 mL | 700.7 mL | 1001 mL |
| 5 mg vial | ||||
| 1 mLCompetitor guide | 5 mg/mL | 200.2 mL | 280.28 mL | 400.4 mL |
| 2 mLCompetitor guide | 2.5 mg/mL | 400.4 mL | 560.56 mL | 800.8 mL |
| 2.5 mLCompetitor guide | 2 mg/mL | 500.5 mL | 700.7 mL | 1001 mL |
| 10 mg vial | ||||
| 3 mLCompetitor guide | 3.333 mg/mL | 300.3 mL | 420.42 mL | 600.6 mL |
| 20 mg vial | ||||
| 0.5 mLRegulatory† | 40 mg/mL | 2.50.025 mL | 3.50.035 mL | 50.05 mL |
| 1 mLCompetitor guide† | 20 mg/mL | 50.05 mL | 70.07 mL | 100.1 mL |
| 1.3 mLRegulatory† | 15.385 mg/mL | 6.50.065 mL | 9.10.091 mL | 130.13 mL |
| 2 mLCompetitor guide† | 10 mg/mL | 100.1 mL | 140.14 mL | 200.2 mL |
| 2.5 mLCompetitor guide† | 8 mg/mL | 12.50.125 mL | 17.50.175 mL | 250.25 mL |
| 3 mLCompetitor guide† | 6.667 mg/mL | 150.15 mL | 210.21 mL | 300.3 mL |
Doses shown are what sources report, labelled by origin. Not medical advice.
Calculate with this peptideYour vial, your water, your dose: Tesamorelin in syringe units, with the math shown.Diluent: Bacteriostatic water (research vials); the Egrifta kits supply their own diluent
Water volumes sources use: 0.5 mL, 1 mL, 1.3 mL, 2 mL, 2.5 mL, 3 mL
Egrifta SV: 2 mg vial plus 0.5 mL supplied sterile water, draw 0.35 mL for a 1.4 mg dose, discard the rest. Egrifta WR: 11.6 mg vial plus 1.3 mL supplied bacteriostatic water, draw 0.16 mL for 1.28 mg; one vial covers 7 daily doses. A 5 mg tesamorelin plus 5 mg ipamorelin blend takes 2 or 3 mL.
Trials used 2 mg once daily. The current labels use 1.4 mg (Egrifta SV) or 1.28 mg (Egrifta WR). All three give the same exposure, so do not compare the raw mg across formulations.
Some protocols start at 1 mg, and trials have used 1 or 2 mg. The visceral-fat results come from 2 mg.
In adults with HIV lipodystrophy, visceral fat fell about 15% over 26 weeks versus placebo, and 17.5% by week 52 in those who stayed on it. Waist size in that group was down 3.4 cm. Fat under the skin did not change.
Seven daily doses. Some protocols run 5 days a week instead.
Guides range widely, from about 100 mcg to 1 mg of tesamorelin per night, because ipamorelin rises with it in a 1:1 blend. That is the biggest dosing inconsistency for this compound. Separate vials let you keep tesamorelin at a trial dose.
One guide uses 3 mL. Use the calculator to turn your dose into syringe units.
Egrifta WR: 7 days after mixing. Egrifta SV: use right away. Research-vial guides say anywhere from 5 days to 30 days.
14 sources, each checked by date. Record updated Oct 23, 2026. Numbers are restated in our own words and labelled by where they came from.
Back to the full Tesamorelin page for side effects, storage, stacks and legal status.